Chiara Melloni

Summary

Affiliation: Duke University Medical Center
Country: USA

Publications

  1. ncbi Safety and efficacy of adjusted-dose eptifibatide in patients with acute coronary syndromes and reduced renal function
    Chiara Melloni
    Division of Cardiology and Duke Clinical Research Institute, Duke University Medical Center, Durham, NC, USA
    Am Heart J 162:884-892.e1. 2011
  2. ncbi Use of early clopidogrel by reperfusion strategy among patients presenting with ST-segment elevation myocardial infarction
    Chiara Melloni
    Division of Cardiology and Duke Clinical Research Institute, Duke University Medical Center, 2400 Pratt St, Durham, NC 27705, USA
    Circ Cardiovasc Qual Outcomes 4:603-9. 2011
  3. ncbi Management of acute coronary syndromes in patients with renal dysfunction
    Chiara Melloni
    Division of Cardiology and Duke Clinical Research Institute, Duke University Medical Center, Durham, North Carolina 27705, USA
    Curr Opin Cardiol 23:320-6. 2008
  4. ncbi Predictors of early discontinuation of evidence-based medicine after acute coronary syndrome
    Chiara Melloni
    Division of Cardiology and Duke Clinical Research Institute, Duke University Medical Center, Durham, North Carolina, USA
    Am J Cardiol 104:175-81. 2009
  5. ncbi Design and rationale of the Evaluation of M118 IN pErcutaNeous Coronary intErvention (EMINENCE) trial
    Chiara Melloni
    Duke Clinical Research Institute, Durham, NC, USA
    Am Heart J 158:726-33. 2009
  6. ncbi Unfractionated heparin dosing and risk of major bleeding in non-ST-segment elevation acute coronary syndromes
    Chiara Melloni
    Division of Cardiology and Duke Clinical Research Institute, Duke University Medical Center, Durham, NC 27705, USA
    Am Heart J 156:209-15. 2008
  7. ncbi Metabolic efficiency with ranolazine for less ischemia in non-ST elevation acute coronary syndromes (MERLIN TIMI-36) study
    Chiara Melloni
    Duke Clinical Research Institute, 2400 Pratt Street, Durham, NC 27705, USA
    Expert Rev Cardiovasc Ther 6:9-16. 2008
  8. ncbi Representation of women in randomized clinical trials of cardiovascular disease prevention
    Chiara Melloni
    Duke Clinical Research Institute, Duke University Medical Center, Durham, NC 27705, USA
    Circ Cardiovasc Qual Outcomes 3:135-42. 2010
  9. ncbi Cockcroft-Gault versus modification of diet in renal disease: importance of glomerular filtration rate formula for classification of chronic kidney disease in patients with non-ST-segment elevation acute coronary syndromes
    Chiara Melloni
    Division of Cardiology and Duke Clinical Research Institute, Duke University Medical Center, Durham, North Carolina 27705, USA
    J Am Coll Cardiol 51:991-6. 2008
  10. ncbi Implications and reasons for the lack of use of reperfusion therapy in patients with ST-segment elevation myocardial infarction: findings from the CRUSADE initiative
    Shahyar Michael Gharacholou
    Duke Clinical Research Institute, Durham, NC, USA
    Am Heart J 159:757-63. 2010

Detail Information

Publications27

  1. ncbi Safety and efficacy of adjusted-dose eptifibatide in patients with acute coronary syndromes and reduced renal function
    Chiara Melloni
    Division of Cardiology and Duke Clinical Research Institute, Duke University Medical Center, Durham, NC, USA
    Am Heart J 162:884-892.e1. 2011
    ..Dose adjustment of renally excreted antithrombotic drugs is recommended for patients with reduced renal function. We examined the influence of dose modification on bleeding and efficacy...
  2. ncbi Use of early clopidogrel by reperfusion strategy among patients presenting with ST-segment elevation myocardial infarction
    Chiara Melloni
    Division of Cardiology and Duke Clinical Research Institute, Duke University Medical Center, 2400 Pratt St, Durham, NC 27705, USA
    Circ Cardiovasc Qual Outcomes 4:603-9. 2011
    ..The 2007 update of the ACC/AHA guidelines for STEMI patients recommended addition of clopidogrel to aspirin regardless of reperfusion strategy, with a bolus dose in patients <75 years of age...
  3. ncbi Management of acute coronary syndromes in patients with renal dysfunction
    Chiara Melloni
    Division of Cardiology and Duke Clinical Research Institute, Duke University Medical Center, Durham, North Carolina 27705, USA
    Curr Opin Cardiol 23:320-6. 2008
    ..Often, patients with chronic kidney disease are excluded from clinical trials, so in clinical practice physicians may not have definitive evidence to support treatment decisions...
  4. ncbi Predictors of early discontinuation of evidence-based medicine after acute coronary syndrome
    Chiara Melloni
    Division of Cardiology and Duke Clinical Research Institute, Duke University Medical Center, Durham, North Carolina, USA
    Am J Cardiol 104:175-81. 2009
    ..Patient education, better prescription drug coverage, and reminder strategies may improve use of EBMs at 3 months after discharge from ACS admission...
  5. ncbi Design and rationale of the Evaluation of M118 IN pErcutaNeous Coronary intErvention (EMINENCE) trial
    Chiara Melloni
    Duke Clinical Research Institute, Durham, NC, USA
    Am Heart J 158:726-33. 2009
    ....
  6. ncbi Unfractionated heparin dosing and risk of major bleeding in non-ST-segment elevation acute coronary syndromes
    Chiara Melloni
    Division of Cardiology and Duke Clinical Research Institute, Duke University Medical Center, Durham, NC 27705, USA
    Am Heart J 156:209-15. 2008
    ..Unfractionated heparin (UFH) is a mainstay of treatment for patients with non-ST-segment elevation acute coronary syndromes (NSTE ACS), but the practice of weight-adjusted bolus and infusion dosing has not been carefully evaluated...
  7. ncbi Metabolic efficiency with ranolazine for less ischemia in non-ST elevation acute coronary syndromes (MERLIN TIMI-36) study
    Chiara Melloni
    Duke Clinical Research Institute, 2400 Pratt Street, Durham, NC 27705, USA
    Expert Rev Cardiovasc Ther 6:9-16. 2008
    ....
  8. ncbi Representation of women in randomized clinical trials of cardiovascular disease prevention
    Chiara Melloni
    Duke Clinical Research Institute, Duke University Medical Center, Durham, NC 27705, USA
    Circ Cardiovasc Qual Outcomes 3:135-42. 2010
    ....
  9. ncbi Cockcroft-Gault versus modification of diet in renal disease: importance of glomerular filtration rate formula for classification of chronic kidney disease in patients with non-ST-segment elevation acute coronary syndromes
    Chiara Melloni
    Division of Cardiology and Duke Clinical Research Institute, Duke University Medical Center, Durham, North Carolina 27705, USA
    J Am Coll Cardiol 51:991-6. 2008
    ..Our purpose was to compare formulae for estimating glomerular filtration rate (GFR) in non-ST-segment elevation acute coronary syndromes (NSTE ACS) patients...
  10. ncbi Implications and reasons for the lack of use of reperfusion therapy in patients with ST-segment elevation myocardial infarction: findings from the CRUSADE initiative
    Shahyar Michael Gharacholou
    Duke Clinical Research Institute, Durham, NC, USA
    Am Heart J 159:757-63. 2010
    ..However, many STEMI patients in contemporary practice still do not receive any form of reperfusion therapy...
  11. ncbi Medical records and quality of care in acute coronary syndromes: results from CRUSADE
    Shannon M Dunlay
    Department of Medicine, Duke University Medical Center, Durham, NC, USA
    Arch Intern Med 168:1692-8. 2008
    ..Patient medical records are important means of communication among health care providers. Limited evaluation has been performed of the quality of the medical records or its association with health care processes or outcomes...
  12. ncbi Age and persistent use of cardiovascular medication after acute coronary syndrome: results from medication applied and sustained over time
    Robin C Ali
    Department of Community and Family Medicine, Duke University Medical Center, Durham, North Carolina 27710, USA
    J Am Geriatr Soc 57:1990-6. 2009
    ..To describe the persistent use of evidence-based cardiovascular medications (EBCMs) 3 months after discharge from an acute coronary syndrome (ACS) event and patient-reported reasons for nonpersistence across age groups...
  13. ncbi Phase 1b randomized study of antidote-controlled modulation of factor IXa activity in patients with stable coronary artery disease
    Mark Y Chan
    Duke Clinical Research Institute, 2400 Pratt St, Terrace Level Room 0311, Durham, NC 27705, USA
    Circulation 117:2865-74. 2008
    ..REG1 consists of RB006 (drug), an injectable RNA aptamer that specifically binds and inhibits factor IXa, and RB007 (antidote), the complementary oligonucleotide that neutralizes its anti-IXa activity...
  14. ncbi Association between patient beliefs and medication adherence following hospitalization for acute coronary syndrome
    Nancy M Allen LaPointe
    Division of Clinical Pharmacology, Duke Clinical Research Institute, Duke University Medical Center, Durham, NC, USA
    Am Heart J 161:855-63. 2011
    ....
  15. ncbi Lipid-lowering intensification and low-density lipoprotein cholesterol achievement from hospital admission to 1-year follow-up after an acute coronary syndrome event: results from the Medications ApplIed aNd SusTAINed Over Time (MAINTAIN) registry
    Chiara Melloni
    Duke Clinical Research Institute and Division of Cardiology, Duke University Medical Center, Durham, NC 27705, USA
    Am Heart J 160:1121-9, 1129.e1. 2010
    ....
  16. ncbi Prognostic value of troponins in patients with non-ST-segment elevation acute coronary syndromes and chronic kidney disease
    Chiara Melloni
    Division of Cardiology and Duke Clinical Research Institute, Duke University Medical Center, Durham, North Carolina, USA
    Clin Cardiol 31:125-9. 2008
    ..The prognostic value of cardiac troponins (cTn) in patients with non-ST-segment elevation acute coronary syndromes (NSTE ACS) and chronic kidney disease (CKD) is debated...
  17. ncbi Evaluation of a new heparin agent in percutaneous coronary intervention: results of the phase 2 evaluation of M118 IN pErcutaNeous Coronary intErvention (EMINENCE) Trial
    Sunil V Rao
    Duke Clinical Research Institute, Durham, NC, USA
    Circulation 121:1713-21. 2010
    ..We performed a phase 2 randomized trial to evaluate the safety and feasibility of M118 in the setting of elective percutaneous coronary intervention...
  18. ncbi The Study Of LoSmapimod treatment on inflammation and InfarCtSizE (SOLSTICE): Design and rationale
    Chiara Melloni
    Duke Clinical Research Institute, Durham, NC Electronic address
    Am Heart J 164:646-653.e3. 2012
    ..Information gained from the SOLSTICE trial will inform further testing of this agent in larger clinical trials...
  19. ncbi Safety and tolerability of SCH 530348 in patients undergoing non-urgent percutaneous coronary intervention: a randomised, double-blind, placebo-controlled phase II study
    Richard C Becker
    Duke Clinical Research Institute, Durham, NC, USA
    Lancet 373:919-28. 2009
    ..We therefore assessed the tolerability and safety of SCH 530348-an oral platelet protease-activated receptor-1 antagonist...
  20. ncbi Changes in beliefs about medications during long-term care for ischemic heart disease
    Nancy M Allen LaPointe
    Division of Clinical Pharmacology and Duke Clinical Research Institute, Duke University Medical Center, Durham NC, USA
    Am Heart J 159:561-9. 2010
    ..Changes in these beliefs during long-term care have not previously been studied and were evaluated for purposes of this analysis...
  21. ncbi Extended-release ranolazine: critical evaluation of its use in stable angina
    Adriano Am Truffa
    Duke Clinical Research Institute and Department of Medicine, Duke University Medical Center, Durham, NC, USA
    Vasc Health Risk Manag 7:535-9. 2011
    ....
  22. ncbi Design and rationale of the Reduction of Infarct Expansion and Ventricular Remodeling with Erythropoietin after Large Myocardial Infarction (REVEAL) trial
    Chiara Melloni
    Division of Cardiology, Department of Medicine, Duke University School of Medicine, Durham, NC, USA
    Am Heart J 160:795-803.e2. 2010
    ..Animal models of ischemia/reperfusion have demonstrated that single-dose erythropoietin may reduce infarct size, decrease apoptosis, and increase neovascularization, possibly through mobilization of endothelial progenitor cells...
  23. ncbi An evaluation of patient self-testing competency of prothrombin time for managing anticoagulation: pre-randomization results of VA Cooperative Study #481--The Home INR Study (THINRS)
    Rowena J Dolor
    Center for Health Services Research in Primary Care, VA Medical Center, Durham, NC, USA
    J Thromb Thrombolysis 30:263-75. 2010
    ..Successful home monitoring of PT with a PST device required adequate levels of cognition and manual dexterity. Training a caregiver modestly increased the proportion of patients who can perform PST...
  24. ncbi First-in-human experience of an antidote-controlled anticoagulant using RNA aptamer technology: a phase 1a pharmacodynamic evaluation of a drug-antidote pair for the controlled regulation of factor IXa activity
    Christopher K Dyke
    Duke Clinical Research Institute, Durham, NC 27715, USA
    Circulation 114:2490-7. 2006
    ..The primary objective was to determine the safety profile and to characterize the pharmacodynamic responses in this first-in-human study...
  25. ncbi Highlights from the American College of Cardiology Annual Scientific Session 2005: March 6 to 9, 2005, Orlando, Florida
    Manesh R Patel
    Division of Cardiology, Department of Medicine, Duke University Medical Center, Durham, NC, USA
    Am Heart J 149:1009-19. 2005
  26. ncbi Highlights from the 56th annual scientific sessions of the American College of Cardiology: March 25 to 27, 2007, Atlanta, Georgia
    George L Adams
    Duke Clinical Research Institute, Durham, NC 27715, USA
    Am Heart J 154:247-59. 2007
  27. ncbi Clinical use of novel antithrombotic agents in the management of acute coronary syndromes
    Giovanni Melandri
    Institute of Cardiology, Bologna University, Italy
    Pathophysiol Haemost Thromb 32:282-8. 2002
    ..All patients with glomerular filtration rate > or = 30 ml/min should receive low molecular weight heparin. Evidence for that is mainly driven by studies using enoxaparin...